Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results.Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion.

BenzingaJul 16 13:06 ET

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday.Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a

BenzingaJul 16 11:09 ET

Fate Therapeutics Shares Are Trading Lower Gaining Monday Following an Analyst Upgrade.

Fate Therapeutics Shares Are Trading Lower Gaining Monday Following an Analyst Upgrade.

BenzingaJun 26 14:35 ET

Fate Therapeutics Down Over 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk

Fate Therapeutics, Inc. ( FATE ) is currently at $3.30, down $0.43 or 11.42% --Would be lowest close since Dec. 20, 2023, when it closed at $3.06 --On pace for largest percent decrease since Jan. 6,

Dow JonesJun 26 13:44 ET

Intellia Therapeutics Named Edward Dulac Of Fate Therapeutics As CFO, Effective July 22, Succeeding Glenn Goddard

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dula

BenzingaJun 26 07:32 ET

Fate Therapeutics Drops To US$3.41, Yet Insiders May Have Sold Too Early

Even though Fate Therapeutics, Inc. (NASDAQ:FATE) has fallen by 12% over the past week , insiders who sold US$222k worth of stock over the past year have had less luck. Insiders might have been bette

Simply Wall StJun 19 08:45 ET